Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other solid neoplasm 1

Conditions

Triple Negative Breast Neoplasms 4Carcinoma, Non-Small-Cell Lung 4Breast Neoplasms 4Carcinoma, Transitional Cell 3Neoplasm Metastasis 2Urinary Bladder Neoplasms 1Recurrent Platinum-Sensitive Fallopian Tube Endometrioid Adenocarcinoma 1Prostatic Neoplasms 1Muscle Invasive Bladder Urothelial Carcinoma 1Lung Neoplasms 1Lung Diseases 1Locally Advanced or Metastatic Unresectable Urothelial Cancer 1Liver Failure 1HRD Cancer 1Extensive Stage Small Cell Lung Cancer (ES-SCLC) 1Drug-Related Side Effects and Adverse Reactions 1Advanced Solid Tumors 1

Interventions

Injections 5pembrolizumab 2Pemetrexed 2Carboplatin 2tislelizumab 1sotorasib 1sacituzumab govitecan 1fludarabine 1WW Domain-Containing Oxidoreductase 1SYS6006 COVID-19 vaccine 1Panitumumab 1Paclitaxel 1Oxaliplatin 1Leucovorin 1Fluorouracil 1Drug Therapy 1Cetuximab 1Antiemetics 14-amino-5-fluoro-3-(5-(4-methylpiperazin-1-yl)-1H-benzimidazol-2-yl)quinolin-2(1H)-one 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Advanced Solid Tumors × sacituzumab govitecan × 30 days × Clear all
NCT06167317 2026-05-28

Study of GS-0201 Alone and in Combination in Participants With Advanced Solid Tumors

Gilead Sciences

Phase 1 Recruiting
278 enrolled
Other solid neoplasm

Advanced Solid Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡